| # | Drug | Count |
|---|---|---|
| 0 | SILDENAFIL CITRATE | 139 |
| 1 | MACITENTAN | 128 |
| 2 | TADALAFIL | 117 |
| 3 | TREPROSTINIL | 117 |
| 4 | SILDENAFIL | 106 |
| 5 | AMBRISENTAN | 93 |
| 6 | SELEXIPAG | 84 |
| 7 | FUROSEMIDE | 81 |
| 8 | BOSENTAN | 80 |
| 9 | SILDENAFIL POWDER, | 74 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETHACRYNATE SODIUM | 1 | 0.1429 |
| 1 | MITOMYCIN | 46 | 0.0126 |
| 2 | EPOPROSTENOL | 57 | 0.0044 |
| 3 | ILOPROST | 4 | 0.0043 |
| 4 | HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN | 2 | 0.0041 |
| 5 | NITRIC OXIDE | 19 | 0.0041 |
| 6 | IDARUBICIN HYDROCHLORIDE | 4 | 0.0035 |
| 7 | SELEXIPAG | 84 | 0.0032 |
| 8 | THIOTEPA | 30 | 0.0031 |
| 9 | GEMTUZUMAB OZOGAMICIN | 11 | 0.0030 |
| # | Drug class | Count |
|---|---|---|
| 0 | Endothelin Receptor Antagonist [EPC] | 216 |
| 1 | Phosphodiesterase 5 Inhibitor [EPC] | 185 |
| 2 | Prostacycline Vasodilator [EPC] | 162 |
| 3 | Alkylating Drug [EPC] | 149 |
| 4 | Loop Diuretic [EPC] | 92 |
| 5 | Prostacyclin Receptor Agonist [EPC] | 84 |
| 6 | Corticosteroid [EPC] | 67 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 58 |
| 8 | Platinum-based Drug [EPC] | 52 |
| 9 | Aldosterone Antagonist [EPC] | 51 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Prostacycline [EPC] | 4 | 0.0043 |
| 1 | Prostacyclin Receptor Agonist [EPC] | 84 | 0.0032 |
| 2 | CD33-directed Immunoconjugate [EPC] | 11 | 0.0030 |
| 3 | Phosphodiesterase 5 Inhibitor [EPC] | 185 | 0.0014 |
| 4 | Prostacycline Vasodilator [EPC] | 162 | 0.0012 |
| 5 | Antihypoglycemic Agent [EPC] | 5 | 0.0012 |
| 6 | Soluble Guanylate Cyclase Stimulator [EPC] | 37 | 0.0011 |
| 7 | Endothelin Receptor Antagonist [EPC] | 216 | 0.0011 |
| 8 | Methylating Agent [EPC] | 1 | 0.0010 |
| 9 | Vasopressin V2 Receptor Antagonist [EPC] | 13 | 0.0009 |